Immunotherapeutic agents currently represented by four groups of drugs
• Immunosuppressive
• Anti -TNF drugs
• intravenous immunoglobulin ( IVIG )
• IFN .
ANTI -TNF DRUGS
Tumor necrosis factor a ( TNFos ) - pro-inflammatory cytokine that plays an important role in the pathogenesis of rheumatic and inflammatory diseases. New data on the value of TSP axes in the pathophysiology of rheumatoid arthritis and Crohn's disease led to the development of a new class of anti - TNFa preparations.
• Immunosuppressive
• Anti -TNF drugs
• intravenous immunoglobulin ( IVIG )
• IFN .
ANTI -TNF DRUGS
Tumor necrosis factor a ( TNFos ) - pro-inflammatory cytokine that plays an important role in the pathogenesis of rheumatic and inflammatory diseases. New data on the value of TSP axes in the pathophysiology of rheumatoid arthritis and Crohn's disease led to the development of a new class of anti - TNFa preparations.
Infliximab ( humanized monoclonal anti FNOos AT ) - approved for the treatment of rheumatoid arthritis and Crohn's disease in the active phase
• Dosage: 5 mg / kg for 2 h / in
• Side effects : viral infection , bronchitis, pneumonia, sinusitis, urinary tract infections , vomiting, diarrhea, headache , dizziness , hypertension
• Contraindications: sepsis, symptomatic infection, abscess, pregnancy, age younger than 17 years .
Комментариев нет:
Отправить комментарий